| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia.
|
J Clin Psychopharmacol
|
2005
|
2.07
|
|
2
|
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.
|
J Clin Psychiatry
|
2005
|
1.91
|
|
3
|
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
|
J Clin Psychopharmacol
|
2007
|
1.66
|
|
4
|
Folate, homocysteine, and negative symptoms in schizophrenia.
|
Am J Psychiatry
|
2004
|
1.65
|
|
5
|
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
|
J Clin Psychiatry
|
2004
|
1.41
|
|
6
|
Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation.
|
Acad Psychiatry
|
2013
|
1.40
|
|
7
|
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
|
J Clin Psychiatry
|
2004
|
1.22
|
|
8
|
SEMAPHORE1 functions during the regulation of ancestrally duplicated knox genes and polar auxin transport in maize.
|
Development
|
2002
|
1.13
|
|
9
|
Developing novel treatments for mood disorders: accelerating discovery.
|
Biol Psychiatry
|
2002
|
1.13
|
|
10
|
Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia.
|
Am J Med Genet B Neuropsychiatr Genet
|
2008
|
1.10
|
|
11
|
Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.
|
Schizophr Res
|
2007
|
1.08
|
|
12
|
Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia.
|
Schizophr Res
|
2007
|
1.07
|
|
13
|
Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia.
|
Psychiatry Res
|
2006
|
1.04
|
|
14
|
Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia.
|
Biol Psychiatry
|
2007
|
1.04
|
|
15
|
Capacity building in global mental health: professional training.
|
Harv Rev Psychiatry
|
2012
|
1.04
|
|
16
|
Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia.
|
Schizophr Res
|
2010
|
1.03
|
|
17
|
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
|
Psychopharmacology (Berl)
|
2004
|
1.01
|
|
18
|
Inflammation and schizophrenia.
|
Expert Rev Neurother
|
2007
|
1.01
|
|
19
|
Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction.
|
J Clin Psychiatry
|
2004
|
0.99
|
|
20
|
Treatment of cardiac risk factors among patients with schizophrenia and diabetes.
|
Psychiatr Serv
|
2006
|
0.98
|
|
21
|
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia.
|
J Clin Psychiatry
|
2005
|
0.96
|
|
22
|
Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia.
|
Psychiatry Res
|
2008
|
0.95
|
|
23
|
Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia.
|
J Clin Psychiatry
|
2010
|
0.94
|
|
24
|
No physical health without mental health: lessons unlearned?
|
Bull World Health Organ
|
2013
|
0.93
|
|
25
|
Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients.
|
Psychiatr Serv
|
2011
|
0.92
|
|
26
|
Sexual functioning, psychopathology and quality of life in patients with schizophrenia.
|
Schizophr Res
|
2007
|
0.88
|
|
27
|
Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.
|
J Clin Psychiatry
|
2009
|
0.88
|
|
28
|
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.
|
Psychopharmacology (Berl)
|
2005
|
0.88
|
|
29
|
Cancer care for individuals with schizophrenia.
|
Cancer
|
2013
|
0.85
|
|
30
|
Psychiatric effects of traumatic brain injury events in Cambodian survivors of mass violence.
|
Br J Psychiatry
|
2002
|
0.85
|
|
31
|
Asymmetric division in fucoid zygotes is positioned by telophase nuclei.
|
Plant Cell
|
2003
|
0.85
|
|
32
|
Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort.
|
Psychosomatics
|
2007
|
0.84
|
|
33
|
A placebo-controlled study of sildenafil effects on cognition in schizophrenia.
|
Psychopharmacology (Berl)
|
2008
|
0.84
|
|
34
|
Sibutramine: current status as an anti-obesity drug and its future perspectives.
|
Expert Opin Pharmacother
|
2008
|
0.83
|
|
35
|
Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.
|
Trials
|
2013
|
0.83
|
|
36
|
Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia.
|
J Clin Psychopharmacol
|
2011
|
0.81
|
|
37
|
An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics.
|
Ann Clin Psychiatry
|
2013
|
0.80
|
|
38
|
Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients.
|
Biol Psychiatry
|
2006
|
0.79
|
|
39
|
Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.
|
Expert Opin Investig Drugs
|
2012
|
0.78
|
|
40
|
No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia.
|
J Clin Psychopharmacol
|
2011
|
0.78
|
|
41
|
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.
|
Schizophr Res
|
2013
|
0.78
|
|
42
|
Open-label pilot study on vitamin D₃ supplementation for antipsychotic-associated metabolic anomalies.
|
Int Clin Psychopharmacol
|
2013
|
0.78
|
|
43
|
Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with schizophrenia.
|
Schizophr Res
|
2010
|
0.78
|
|
44
|
Impact of a metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic.
|
Acad Psychiatry
|
2012
|
0.77
|
|
45
|
Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia.
|
Schizophr Res
|
2006
|
0.77
|
|
46
|
Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
|
J Clin Psychopharmacol
|
2016
|
0.77
|
|
47
|
Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR).
|
Psychiatry Res
|
2010
|
0.77
|
|
48
|
Development of high-yield autofluorescent protein microarrays using hybrid cell-free expression with combined Escherichia coli S30 and wheat germ extracts.
|
Proteome Sci
|
2010
|
0.76
|
|
49
|
Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
|
Psychiatry Res
|
2012
|
0.76
|
|
50
|
No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia.
|
J Clin Psychopharmacol
|
2013
|
0.76
|
|
51
|
Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder.
|
Evid Based Ment Health
|
2012
|
0.76
|
|
52
|
Both physical activity and food intake are associated with metabolic risks in patients with schizophrenia.
|
Schizophr Res
|
2012
|
0.75
|
|
53
|
Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.
|
J Psychiatr Pract
|
2016
|
0.75
|
|
54
|
Posttraumatic Stress Disorder Symptoms and Social and Occupational Functioning of People With Schizophrenia.
|
J Nerv Ment Dis
|
2016
|
0.75
|
|
55
|
Delineating responsibility: primary care provider perspective.
|
Psychiatr Serv
|
2015
|
0.75
|
|
56
|
Low-dose clozapine and diabetic ketoacidosis.
|
Psychosomatics
|
2003
|
0.75
|